We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

191 hedge funds and large institutions have $2.56B invested in Array Biopharma Inc in 2017 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 75 increasing their positions, 57 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more call options, than puts

Call options by funds: $44M | Put options by funds: $22.5M

75% more funds holding in top 10

Funds holding in top 10: 4 → 7 (+3)

32% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 57

25% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 28

6% more capital invested

Capital invested by funds: $2.41B → $2.56B (+$154M)

4% more funds holding

Funds holding: 184 → 191 (+7)

Holders
191
Holders Change
+7
Holders Change %
+3.8%
% of All Funds
4.33%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.16%
New
35
Increased
75
Reduced
57
Closed
28
Calls
$44M
Puts
$22.5M
Net Calls
+$21.5M
Net Calls Change
+$20.1M

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$26M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$22M
3
State Street
State Street
Massachusetts
+$21.1M
4
BlackRock
BlackRock
New York
+$19.4M
5
EC
EcoR1 Capital
California
+$18.6M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$74.6M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$37.5M
3
PC
PointState Capital
New York
-$16.8M
4
Citadel Advisors
Citadel Advisors
Florida
-$16.5M
5
Two Sigma Investments
Two Sigma Investments
New York
-$13M
Name Holding Trade Value Shares
Change 		Change in
Stake
RhumbLine Advisers
76
RhumbLine Advisers
Massachusetts
$2.47M -$203K -17,874 -8%
Ameriprise
77
Ameriprise
Minnesota
$2.46M +$777K +68,316 +55%
Nisa Investment Advisors
78
Nisa Investment Advisors
Missouri
$2.34M – – –
PPA
79
Parametric Portfolio Associates
Washington
$2.29M +$157K +13,798 +8%
WMSA
80
Weiss Multi-Strategy Advisers
New York
$2.24M +$28.4K +2,500 +1%
BTS
81
BB&T Securities
Virginia
$2.22M – – –
Citigroup
82
Citigroup
New York
$2.21M +$753K +66,236 +62%
Canada Pension Plan Investment Board
83
Canada Pension Plan Investment Board
Ontario, Canada
$2.17M +$1.79M +157,600 +1,313%
State of Wisconsin Investment Board
84
State of Wisconsin Investment Board
Wisconsin
$2.16M +$467K +41,100 +32%
EI
85
EAM Investors
California
$2.1M -$438K -38,491 -19%
Fisher Asset Management
86
Fisher Asset Management
Washington
$2.07M +$310K +27,253 +20%
Russell Investments Group
87
Russell Investments Group
United Kingdom
$1.95M -$294K -25,840 -15%
Manulife (Manufacturers Life Insurance)
88
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.94M +$230K +20,190 +15%
Parallax Volatility Advisers
89
Parallax Volatility Advisers
California
$1.82M +$1.62M +142,019 New
HCM
90
Hollencrest Capital Management
California
$1.81M – – –
First Trust Advisors
91
First Trust Advisors
Illinois
$1.77M +$24.2K +2,125 +2%
ProShare Advisors
92
ProShare Advisors
Maryland
$1.74M +$310K +27,278 +25%
AIG
93
American International Group
New York
$1.72M +$209K +18,401 +16%
Hudson Bay Capital Management
94
Hudson Bay Capital Management
Connecticut
$1.6M +$284K +25,000 +25%
XSC
95
X-Square Capital
Puerto Rico
$1.51M +$1.34M +118,158 New
TI
96
Trexquant Investment
Connecticut
$1.46M +$1.29M +113,813 New
KIA
97
Kopp Investment Advisors
Minnesota
$1.44M -$78.7K -6,917 -6%
Legal & General Group
98
Legal & General Group
United Kingdom
$1.33M +$253K +22,205 +27%
UBS Group
99
UBS Group
Switzerland
$1.23M +$26.3K +2,312 +2%
Neuberger Berman Group
100
Neuberger Berman Group
New York
$1.23M +$372K +32,725 +52%
2 3
4
5 6

ARRY Hedge Fund Activity: Q4 2017 in Review

191 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q4 2017, worth a combined $2.56B — up 6.4% from $2.41B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ARRY positions and 28 closed out — a net gain of 7 holders — while 75 added to existing stakes and 57 trimmed.

The largest buyer was BVF Inc, adding an estimated $26M. The largest seller was OrbiMed, cutting an estimated $74.6M.

  • 191 institutional investors held Array Biopharma Inc (ARRY) as of Q4 2017, up from 184 in Q3 2017.
  • Funds reported $2.56B of Array Biopharma Inc stock for Q4 2017, up 6.4% quarter-over-quarter.
  • 35 funds opened new Array Biopharma Inc positions in Q4 2017 and 28 closed out, a net change of +7 holders.
  • The largest Array Biopharma Inc buyer in Q4 2017 was BVF Inc, an estimated $26M added.
  • The largest Array Biopharma Inc seller in Q4 2017 was OrbiMed, an estimated $74.6M sold.

Based on aggregated 13F filings for Q4 2017.